Cowen and Company set a $280.00 price target on Allergan PLC. (NYSE:AGN) in a report released on Friday. The brokerage currently has a buy rating on the stock.

AGN has been the topic of a number of other research reports. Royal Bank Of Canada restated an outperform rating and set a $250.00 price objective (down previously from $277.00) on shares of Allergan PLC. in a research note on Thursday. They noted that the move was a valuation call. Vetr upgraded Allergan PLC. from a sell rating to a hold rating and set a $242.88 price objective on the stock in a research note on Monday, June 26th. BidaskClub lowered Allergan PLC. from a sell rating to a strong sell rating in a research note on Friday, August 25th. Mizuho restated a buy rating and set a $267.00 price objective on shares of Allergan PLC. in a research note on Monday, September 25th. Finally, Wells Fargo & Company restated an outperform rating and set a $258.00 price objective on shares of Allergan PLC. in a research note on Wednesday, October 18th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and twelve have issued a buy rating to the stock. Allergan PLC. currently has a consensus rating of Hold and an average target price of $252.39.

Shares of Allergan PLC. (AGN) opened at 188.28 on Friday. Allergan PLC. has a one year low of $182.80 and a one year high of $256.80. The firm has a market cap of $62.94 billion, a price-to-earnings ratio of 5.74 and a beta of 1.15. The stock’s 50 day moving average price is $211.30 and its 200 day moving average price is $230.36.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. During the same quarter last year, the company earned $3.35 EPS. The company’s revenue was up 8.8% on a year-over-year basis. On average, equities analysts anticipate that Allergan PLC. will post $16.21 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Cowen and Company Reiterates $280.00 Price Target for Allergan PLC. (AGN)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/23/cowen-and-company-reiterates-280-00-price-target-for-allergan-plc-agn.html.

Allergan PLC. announced that its board has authorized a stock buyback plan on Monday, September 25th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its stock is undervalued.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGN. Howard Hughes Medical Institute acquired a new position in Allergan PLC. during the 2nd quarter worth about $103,000. Rockefeller Financial Services Inc. lifted its holdings in Allergan PLC. by 283.7% during the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after buying an additional 400 shares during the period. Jacobi Capital Management LLC lifted its holdings in Allergan PLC. by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the period. JNBA Financial Advisors lifted its holdings in Allergan PLC. by 2.5% during the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the period. Finally, Massey Quick & Co. LLC lifted its holdings in Allergan PLC. by 334.8% during the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock worth $122,000 after buying an additional 385 shares during the period. 81.94% of the stock is currently owned by institutional investors.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.